Evidence map›Paper›PMID 35267635›Full record

ArticleCancers2022

Management and Outcome of Young Women (≤40 Years) with Breast Cancer in Switzerland.

Giacomo Montagna, Robin Schaffar, Andrea Bordoni, Alessandra Spitale, Daniela A Terribile, Lorenzo Rossi, Yvan Bergeron, Bernadette W A van der Linden, Isabelle Konzelmann, Sabine Rohrmann and 6 more

Abstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Giacomo MontagnaBreast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10001, USA.ORCID 0000-0003-3511-369X
Robin SchaffarGeneva Cancer Registry, University of Geneva, 1205 Geneva, Switzerland.
Andrea BordoniTicino Cancer Registry, Cantonal Institute of Pathology, 6600 Locarno, Switzerland.
Alessandra SpitaleTicino Cancer Registry, Cantonal Institute of Pathology, 6600 Locarno, Switzerland.
Daniela A TerribileDipartimento di Scienze Mediche e Chirurgiche, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
Lorenzo RossiOncology Institute of Southern Switzerland, 6500 Bellinzona, Switzerland.
Yvan BergeronFribourg Cancer Registry, 1705 Fribourg, Switzerland.
Bernadette W A van der LindenFribourg Cancer Registry, 1705 Fribourg, Switzerland.ORCID 0000-0002-4815-2121
Isabelle KonzelmannValais Health Observatory (OVS), 1950 Sion, Switzerland.
Sabine RohrmannCancer Registry Zurich, Zug, Schaffhausen and Schwyz, University Hospital Zurich, 8091 Zurich, Switzerland.
Katharina StaehelinBasel Cancer Registry, 4001 Basel, Switzerland.
Manuela Maspoli-ConconiNeuchâtel and Jura Cancer Registry, 2000 Neuchâtel, Switzerland.
Jean-Luc BulliardNeuchâtel and Jura Cancer Registry, 2000 Neuchâtel, Switzerland.ORCID 0000-0001-9750-2709
Francesco MeaniBreast Unit of Southern Switzerland, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland.
Olivia PaganiBreast Unit of Southern Switzerland, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland.
Elisabetta RapitiGeneva Cancer Registry, University of Geneva, 1205 Geneva, Switzerland.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748Swiss Cancer League HSR-4078-11-2016
6 · The paper itself

Abstract

Background: An increase in breast cancer (BC) incidence in young women (YW) as well as disparities in BC outcomes have been reported in Switzerland. We sought to evaluate treatment and outcome differences among YW with BC (YWBC). Methods: YW diagnosed with stage I-III BC between 2000−2014 were identified through nine cancer registries. Concordance with international guidelines was assessed for 12 items covering clinical/surgical management, combined in a quality-of-care score. We compared score and survival outcome between the two linguistic-geographic regions of Switzerland (Swiss-Latin and Swiss-German) and evaluated the impact of quality-of-care on survival. Results: A total of 2477 women were included. The median age was 37.3 years (IQR 34.0−39.4 years), with 50.3% having stage II BC and 70.3% having estrogen receptor positive tumors. The mean quality-of-care score was higher in the Latin region compared to the German region (86.0% vs. 83.2%, p < 0.0005). Similarly, 5- and 10-year overall survival rates were higher in the Latin compared to the German region (92.3% vs. 90.2%, p = 0.0593, and 84.3% vs. 81.5%, p = 0.0025, respectively). There was no difference in survival according to the score. In the univariate analysis, women in the Latin region had a 28% lower mortality risk compared to women in the German region (hazard ratio 0.72; 95% CI 0.59−0.89). In the multivariable analysis, only stage, differentiation, tumor subtype and treatment period remained independently associated with survival. Conclusions: We identified geographic disparities in the treatment and outcome of YWBC in Switzerland. National guidelines for YWBC should be implemented to standardize treatment. Awareness should be raised among YW and clinicians that BC does not discriminate by age.

Indexed as

breast cancermanagementoutcomeSwitzerlandyoung women

Identifiers

PMID35267635
PMCPMC8909610

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.